Anesthesia & Analgesia · 1998 · 11 citations · 16 references
MedicineAnesthesiologyPharmacologyNeuropharmacologyPain MedicinePharmacodynamicsAnalgesiaAnalgesic PharmacologyNociceptive PainOpioid AnalgesicsOpioid PharmacologyPharmacologic Pain TherapyAnalgesic EffectsDose Addition ModelsDose ResponseNociceptive MechanismsPain PharmacologyPharmacological Pain ReliefSubarachnoid SpaceSystemic Administration
We evaluated the antinociceptive effect of combined spinal administration of morphine and systemic administration of buprenorphine.Experiments were performed on male Wistar rats. Nociception was measured using the tail immersion test. Buprenorphine was injected intraperitoneally (IP) and morphine was injected intrathecally (IT) via a catheter implanted in the subarachnoid space. Interaction of drugs was analyzed using a dose addition model. Both IT (1-5 [micro sign]g) morphine and IP (50-500 [micro sign]g/kg) buprenorphine increased the latencies of nociceptive responses in a dose-dependent manner. IT morphine (4 [micro sign]g) and IP buprenorphine (100 [micro sign]g/kg) produced 62.9 +/- 6.3 and 48.8 +/- 6.6 percent of the maximal possible effect (%MPE), respectively. The combined administration of 2 [micro sign]g of IT morphine and 50 [micro sign]g/kg IP buprenorphine produced a %MPE of 97.1 +/- 3.4. The analysis of drug interaction revealed that IT morphine interacted with IP buprenorphine in a supraadditive manner while producing a potent antinociceptive effect. Implications: The concurrent administration of spinal morphine and systemic buprenorphine produces an antinociceptive effect that is greater than what could have been predicted from individual dose-response curves. This mode of interaction allows maintenance at a significant level of analgesia with reduced doses of opioids, which minimizes the incidence of undesirable side effects. (Anesth Analg 1998;87:583-6)
16
Rostral Spread of Epidural Morphine
Philip R. Bromage, Enrico M. Camporesi, Philippe A. C. Durant et al. · Anesthesiology · 1982 · 341 citations · Full text
Joseph C. Yeung, Thomas A. Rudy · Journal of Pharmacology and Experimental Therapeutics · 1980 · 277 citations
Medicine, Neuroscience, Pharmacology +17
Buprenorphine has potent kappa opioid receptor antagonist activity
Jacob Leander · Neuropharmacology · 1987 · 139 citations